Trials / Terminated
TerminatedNCT02049281
A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)
A Phase I Dose Escalation Study Evaluating MK-8109 (Vintafolide) in Japanese Subjects With Advanced Solid Tumor
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Endocyte · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate thrice weekly dosing with vintafolide to find the maximum tolerable dose. The primary study hypothesis is that administration of vintafolide to participants with advanced solid tumors will have acceptable safety and tolerability.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vintafolide | Intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles. |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2014-05-01
- Completion
- 2014-05-01
- First posted
- 2014-01-30
- Last updated
- 2015-02-10
Source: ClinicalTrials.gov record NCT02049281. Inclusion in this directory is not an endorsement.